The expectation is for a new Congress to create policy around AI and cybersecurity, says Tom Leary of HIMSS.
The company also reported Q3 2024 earnings, noting total revenue of $76.4 million, adjusted EBITDA of $7.3 million and a net loss of $14.7 million.
The acquisition includes all of NeuroReality's assets, including its flagship rehabilitation product, Koji's Quest.
The company will use the funds to expand in Asian and U.S. markets, advance its AI algorithms and grow its workforce.
The aim of the alliance is to collect insights on patient outcomes and drug effectiveness with the Dario Connect platform.
The funding will support clinical trials for the company's NeuroHawk brain-scanning device.
The company reported a 77% YOY increase in revenue in Q3 2024 and plans to release a generic version of Novo Nordisk's GLP-1 drug on its platform in 2025.
The acquisition includes Jack's Canadian clinical assets, the authority to operate 16 medical clinics across 13 Canadian cities and the rights to operate clinics in Walmart stores in Canada.
The company offers a marketplace for individuals seeking addiction and mental health treatment. It will use the funds to scale its workforce and expand its reach.
This marks AITRICS's first foray into Southeast Asia, with applications for regulatory clearance in Indonesia and Malaysia underway.
